Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Atenolol
Sandoz Ltd
C07AB03
Atenolol
25mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
The name of your medicine is Atenolol 25mg/50mg/100mg Tablets. They contain the active ingredient called Atenolol. Atenolol belongs to a group of medicines called beta blockers. It works by slowing the heart rate and relaxing the blood vessels so the heart does not have to pump as hard. Atenolol Tablets may be used for: • high blood pressure • relief of chest pain (angina) • controlling heart beats which are irregular or too fast • early treatment of myocardial infarction (heart attack) DO NOT TAKE ATENOLOL TABLETS IF YOU: • are allergic (hypersensitive) to Atenolol or any of the other ingredients of Atenolol Tablets. See section 6. An allergic reaction may include a rash, itching, difficulty breathing or swelling of the face, lips, throat or tongue • have slow heart beat or low blood pressure • have or ever had cardiogenic shock (heart problem) • have heart or blood vessel disease including untreated heart failure (due to recent heart attack), • have peripheral artery disease (poor circulation in the legs or feet due to narrow or blocked arteries) • have disturbances in heart rhythm including sick sinus syndrome (irregular heart beat) or heart block • have high blood pressure due to a tumour near the kidney (phaeochromocytoma) • have ‘metabolic acidosis’ abnormal chemical levels in the blood such as potassium, sodium, calcium and urea • have untreated phaeochromocytoma (rare tumour that usually starts in the cells of one of your adrenal glands). TAKE SPECIAL CARE WITH ATENOLOL TABLETS IF YOU HAVE: • heart failure or disease that is being controlled • chest pain (Prinzmetal’s angina) • Raynaud’s disease (poor circulation causing cold hands) • any kind of heart problems • suffer from lung disorders • are a diabetic • have myasthenia gravis is a chronic disease characterised by fluctuating levels of muscle weakness. • have history of hypersensitivity • a family history of heart disease or stroke • hypoglycaemia (low blood sugar). Atenolol may hide the symptoms o Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atenolol 25mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Atenolol 25mg For excipients, see 6.1. 3 PHARMACEUTICAL FORM White, circular, biconvex, uncoated tablets with ‘FIL’ engraved above the score line, ‘25’ below the score line, on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atenolol 25mg tablets are indicated for the management of: Hypertension Angina pectoris Cardiac arrhythmias Acute myocardial infarction, as early intervention. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults: _ _ _Hypertension: _ _ _ The majority of patients respond to a single oral dose of 100mg daily though some patients respond to 50mg, the effect being established fully after one or two weeks. A further reduction in blood pressure may be obtained by combining atenolol tablets with other antihypertensive therapy such as diuretics. _Angina: _ The majority of patients respond to a single oral dose of 100mg daily or to 50mg given twice daily. Increasing the dose above l00mg daily is unlikely to confer additional benefit. _Cardiac arrhythmias. _ _ _ The initial dose for control of arrhythmias by intravenous application of atenolol is 2.5mg. This dose may be administered in intervals of 5 minutes until the recommended effect is observed or until the maximum dose of 0.15mg per kg of body weight has been reached, respectively. When the arrhythmia has been controlled with intravenous atenolol, the recommended oral maintenance dose of Atenolol tablets is a single daily dose of 50 - 100mg. _ _ _Myocardial infarction: _ _ _ In those patients who are considered suitable for beta-blocker therapy (presenting for treatment within 12 hours of the onset of chest pain), appropriate intravenous beta-blocker therapy should be supplemented 15 minutes later by a single oral dose of 50mg atenolol tablet providing intravenous therapy has been well tolerated. A further oral dose of 50mg Atenolol tablet should be given 12 hours later fo Read the complete document